Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VAL 301 - ValiRx

Next Previous
X
Search
Drug Profile

VAL 301 - ValiRx

Alternative Names: VAL-301 - ValiRx

Latest Information Update: 18 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ValiRx
  • Class Peptides
  • Mechanism of Action Src-family kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Endometriosis

Most Recent Events

  • 17 Jun 2024 ValiRx has patent protection for VAL 301 in Australia, China, the Europe, Russia and the US, before June 2024 (ValiRx pipeline, June 2024)
  • 17 Jun 2024 ValiRx has patents pending for VAL 301, worldwide (ValiRx pipeline, June 2024)
  • 17 Jun 2024 Preclinical trials in Endometriosis in United Kingdom (unspecified route), before June 2024 (ValiRx pipeline, June 2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top